CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure Dapagliflozin for treating chronic heart failure with reduced ejection fraction

Clinical TrialVolume 73, Issue 1, January 2019

JOURNAL:J Am Coll Cardiol. Article Link

Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women

P Dewan, R Rørth, JJV McMurray et al. Keywords: HFrEF; gender; comorbidity; mortality; quality of life

FULL TEXT PDF